<div><div></div><div>Cellectar Biosciences appointed Andrew Gu to its board as a Class III director and Audit Committee member, while Stefan D. Loren informed the board he will not stand for reelection and will provide consulting services starting July 8, 2026.<div><table><tbody><tr><td>Individual</td><td>Andrew Gu</td><td>Stefan D. Loren, Ph.D.</td></tr><tr><td>Role</td><td>Class III director; member, Audit Committee</td><td>Class III director (term expiring at 2026 annual meeting)</td></tr><tr><td>Type of Change</td><td>Appointed</td><td>Not standing for reelection; consulting agreement</td></tr><tr><td>Effective Date</td><td>May 18, 2026</td><td>Not standing for reelection notified May 17, 2026; consulting agreement effective July 8, 2026</td></tr><tr><td>Reason</td><td>Appointment pursuant to Board Designation Side Letter with Nantahala (Nantahala selected Mr. Gu)</td><td>Chose not to stand for reelection; decision not due to any disagreement with the Company</td></tr><tr><td>Replacement Info</td><td>N/A</td><td>Successor to be determined at annual meeting (term expires at 2026 annual meeting)</td></tr><tr><td>Background Details</td><td>Analyst at Nantahala focusing on biotech investments since June 2021; BS in Economics (Finance) and BA in Neuroscience from University of Pennsylvania (Vagelos Life Sciences &amp; Management Program)</td><td>Will provide one-year consulting services promoting Company success; compensated $15,000 per quarter and granted 15,000 stock option at term end; options exercisable for 10 years from grant dates</td></tr><tr><td>Board/Committee Role Changes</td><td>Appointed to Audit Committee</td><td>Not disclosed</td></tr></tbody></table></div>Original SEC Filing: Cellectar Biosciences, Inc. [ CLRB ] - 8-K - May. 18, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

CLRB

Cellectar Biosciences has appointed Andrew Gu as a Class III director and member of the Audit Committee, effective May 18, 2026. Stefan D. Loren will not seek reelection and will transition to a consulting role starting July 8, 2026. Gu's appointment follows a selection by Nantahala, and Loren's decision is not due to any disagreement with the company.

TradingView

Cellectar Bioscience

VanEck Biotech ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Global Healthcare

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares US Pharma

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant